Predictive Value of C-Peptide Measures for Clinical Outcomes of beta-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)
01/2023
Journal Article
Authors:
Baidal, D. A.;
Ballou, C. M.;
Rickels, M. R.;
Berney, T.;
Pattou, F.;
Payne, E. H.;
Barton, F. B.;
Alejandro, R.;
Citr Investigators
Volume:
46
Pagination:
697-703
Issue:
4
Journal:
Diabetes Care
PMID:
36657975
URL:
https://www.ncbi.nlm.nih.gov/pubmed/36657975
Keywords:
Humans *Diabetes Mellitus, Type 1/surgery/drug therapy C-Peptide Blood Glucose Glycated Hemoglobin *Islets of Langerhans Transplantation Insulin/therapeutic use Glucose/therapeutic use Hypoglycemic Agents/therapeutic use
Insulin, Regular, Human/therapeutic use
Abstract:
OBJECTIVE: To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplant (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS: We evaluated Collaborative Islet Transplant Registry (CITR) islet-alone recipients with pretransplant C-peptide <0.1 nmol/L and mean follow-up of 4.6 +/- 1.1 years (n = 677). Receiver operating characteristic area under the curve (ROC-AUC) was used to evaluate the predictive value of fasting and stimulated glucose and C-peptide measures for seven primary outcomes: 1) absence of severe hypoglycemic events (ASHEs); 2) HbA1c <7.0%; 3) HbA1c <7.0% and ASHEs; 4) HbA1c </=6.5%; 5) HbA1c </=6.5% and ASHEs; 6) insulin independence; and 7) ASHEs, HbA1c </=6.5%, and insulin independence (the optimal outcome). Measures with the highest ROC-AUC were selected for determination of optimal cut points. RESULTS: Fasting C-peptide was highly predictive for ASHE (ROC-AUC 0.906; optimal cut point 0.070 nmol/L) and the optimal outcome (ROC-AUC 0.845; optimal cut point 0.33 nmol/L). Mixed-meal tolerance test (MMTT)-stimulated C-peptide-to-glucose ratio (CPGR) outperformed both fasting and stimulated C-peptide for all outcomes except ASHE. The optimal cut point for the optimal outcome was 0.12 nmol/mmol for MMTT-stimulated CPGR and 0.97 nmol/L for MMTT-stimulated C-peptide. CONCLUSIONS: Fasting C-peptide reliably predicts ITx primary outcomes. MMTT-stimulated CPGR provides marginally better prediction for composite ITx outcomes, including insulin independence. In the absence of an MMTT, a fasting C-peptide >/=0.33 nmol/L is a reassuring measure of optimal islet graft function. C-peptide targets represent excellent and easily determinable means to predict glycemic control outcomes after ITx and should be considered as potential goals of beta-cell replacement.
